pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2016-26-3-352-356pulmo-727Research ArticleОБЗОРЫREVIEWНовые ингаляционные устройства для терапии хронической обструктивной болезни легкихNovel inhalation devices for treatment of chronic obstructive pulmonary diseaseАрхиповВ. В.ArkhipovV. V.

д. м. н., профессор кафедры клинической фармакологии ГБОУ ВПО «Первый московский государственный медицинский университет им. И.М.Сеченова» Минздрава России; тел.: (495) 9155801

MD, Professor at Department of Clinical Pharmacology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia; tel.: (495) 9155801

arkhipov@gmx.usАрхиповаД. Е.ArkhipovaD. E.

к. м. н., ассистент кафедры клинической фармакологии и пропедевтики внутренних болезней ГБОУ ВПО «Первый московский государственный медицинский университет им. И.М.Сеченова» Минздрава России; тел.: (495) 9155801

PhD, Assistant Lecturer at Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia; tel.: (495) 9155801

d2414942@icloud.comЛазареваН. Б.LazarevaN. B.

д. м. н., профессор кафедры клинической фармакологии ГБОУ ВПО «Первый московский государственный медицинский университет им. И.М.Сеченова» Минздрава России; тел.: (495) 9155801

MD, Professor at Department of Clinical Pharmacology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia; tel.: (495) 9155801

natalia.lazareva@gmail.comГБОУ ВПО «Первый московский государственный медицинский университет им. И.М.Сеченова» Минздрава России: 119991, Москва, ул. Трубецкая, 8, стр. 2РоссияI.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia: 8, build. 2, Trubetskaya str., Moscow, 119991, RussiaRussian Federation201627072016263352356Copyright © Архипов В.В., Архипова Д.Е., Лазарева Н.Б., 20162016Архипов В.В., Архипова Д.Е., Лазарева Н.Б.Arkhipov V.V., Arkhipova D.E., Lazareva N.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/727

Целью настоящего обзора является ознакомление с техническими характеристиками и возможностями ингаляторов для терапии хронической обструктивной болезни легких, которые появились в последние годы. Подробно рассмотрены такие устройства, как Бризхалер, Эллипта, Дженуйэр, Некстхалер и Респимат.

The aim of this review was to introduce readers to technical characteristics and advantages of recently available inhalers used for treatment of chronic obstructive pulmonary disease. Such inhalation devices as Breezehaler, Ellipta, Genuair, NEXThaler, and Respimat were described in details in this article.

хроническая обструктивная болезнь легкихпорошковые ингаляторыРеспимат.chronic obstructive pulmonary diseasedry powder inhalersRespimatReferencesLaube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1331.Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1331.Rootmensen G.N., van Keimpema A.R., Jansen H.M., de Haan R.J. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (5): 323–328.Rootmensen G.N., van Keimpema A.R., Jansen H.M., de Haan R.J. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (5): 323–328.Pothirat C., Chaiwong W., Phetsuk N. et al. Evaluating inhaler use technique in COPD patients. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 1291–1298.Pothirat C., Chaiwong W., Phetsuk N. et al. Evaluating inhaler use technique in COPD patients. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 1291–1298.Alaboud A., Assi K.H., and Chrystyn H. In vitro characterization of the emitted dose from the foradil Aerolizer to identify the influence of inhalation flow, inhalation volume and the number of inhalations per dose. Respiratory Drug Delivery. 2012; 3: 803–806.Alaboud A., Assi K.H., and Chrystyn H. In vitro characterization of the emitted dose from the foradil Aerolizer to identify the influence of inhalation flow, inhalation volume and the number of inhalations per dose. Respiratory Drug Delivery. 2012; 3: 803–806.Azouz W., Chetcuti P., Hosker H.S. et al. The inhalation characteristics of patients when they use different dry powder inhalers. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (1): 35–42.Azouz W., Chetcuti P., Hosker H.S. et al. The inhalation characteristics of patients when they use different dry powder inhalers. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (1): 35–42.Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2"agonist particle size. Am. J. Respir. Crit. Care Med. 2005; 172 (12): 1497–1504.Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2"agonist particle size. Am. J. Respir. Crit. Care Med. 2005; 172 (12): 1497–1504.Colice G., Martin R.J., Israel E. et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J. Allergy Clin. Immunol. 2013; 132 (1): 45–54.Colice G., Martin R.J., Israel E. et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J. Allergy Clin. Immunol. 2013; 132 (1): 45–54.Zanen P., Go L.T., Lammers J.W. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996; 51 (10): 977–980.Zanen P., Go L.T., Lammers J.W. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996; 51 (10): 977–980.Criée C.P., Meyer T., Petro W. et al. In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single"dose capsule inhaler. J. Aerosol. Med. 2006; 19 (4): 466–472.Criée C.P., Meyer T., Petro W. et al. In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single"dose capsule inhaler. J. Aerosol. Med. 2006; 19 (4): 466–472.Colthorpe P., Voshaarb T., Kieckbusch T. et al. Delivery characteristics of a low"resistance dry"powder inhaler used to deliver the longacting muscarinic antagonist glycopyrronium. J. Drug Ass. 2013; 2: 11–16.Colthorpe P., Voshaarb T., Kieckbusch T. et al. Delivery characteristics of a low"resistance dry"powder inhaler used to deliver the longacting muscarinic antagonist glycopyrronium. J. Drug Ass. 2013; 2: 11–16.Chapman K.R., Fogarty C.M., Peckitt C. et al. Delivery characteristics and patients' handling of two single"dose dry"powder inhalers used in COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 353–363.Chapman K.R., Fogarty C.M., Peckitt C. et al. Delivery characteristics and patients' handling of two single"dose dry"powder inhalers used in COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 353–363.Demoly P., Hagedoorn P., de Boer A.H., Frijlink H.W. The clinical relevance of dry powder inhaler performance for drug delivery. Respir. Med. 2014; 108 (8): 1195–1203.Demoly P., Hagedoorn P., de Boer A.H., Frijlink H.W. The clinical relevance of dry powder inhaler performance for drug delivery. Respir. Med. 2014; 108 (8): 1195–1203.Malmberg L.P., Rytilä P., Happonen P., Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 257–262.Malmberg L.P., Rytilä P., Happonen P., Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 257–262.Weuthen T., Roeder S., Brand P. et al. In vitro testing of two formoterol dry powder inhalers at different flow rates. J. Aerosol. Med. 2002; 15 (3): 297–303.Weuthen T., Roeder S., Brand P. et al. In vitro testing of two formoterol dry powder inhalers at different flow rates. J. Aerosol. Med. 2002; 15 (3): 297–303.Alaboud S.S. In"vitro inhalation performance for formoterol dry powder and metred dose inhalers. University of Bradford; 2011. https://bradscholars.brad.ac.uk/bitstream/handle/10454/5686/Final_Ph.D 12.4.2012pdf.pdf?sequence=1 Date last accessed: June 14, 2016.Alaboud S.S. In"vitro inhalation performance for formoterol dry powder and metred dose inhalers. University of Bradford; 2011. https://bradscholars.brad.ac.uk/bitstream/handle/10454/5686/Final_Ph.D 12.4.2012pdf.pdf?sequence=1 Date last accessed: June 14, 2016.Hamilton M., Leggett R., Pang C. et al. In vitro dosing performance of the ellipta dry powder inhaler using asthma and COPD patient inhalation profiles replicated with the electronic lung (eLung™). J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (6): 498–506.Hamilton M., Leggett R., Pang C. et al. In vitro dosing performance of the ellipta dry powder inhaler using asthma and COPD patient inhalation profiles replicated with the electronic lung (eLung™). J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (6): 498–506.Ciciliani A., Wachtel H., Langguth P. Comparing Respimat® Soft Mist™ inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respir. Drug Delivery. 2014; 2: 453–456.Ciciliani A., Wachtel H., Langguth P. Comparing Respimat® Soft Mist™ inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respir. Drug Delivery. 2014; 2: 453–456.Newman S.P., Sutton D.J., Segarra R. et al. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009; 78 (3): 322–328.Newman S.P., Sutton D.J., Segarra R. et al. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009; 78 (3): 322–328.Corradi M., Chrystyn H., Cosio B.G. et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Exp. Opin. Drug Deliv. 2014; 11 (9): 1497–1506.Corradi M., Chrystyn H., Cosio B.G. et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Exp. Opin. Drug Deliv. 2014; 11 (9): 1497–1506.Scichilone N. Asthma control: the right inhaler for the right patient. Adv. Ther. 2015; 32 (4): 285–292.Scichilone N. Asthma control: the right inhaler for the right patient. Adv. Ther. 2015; 32 (4): 285–292.Pasquali I. et al. Poster presentation at the 2012 AAPS Annual Meeting and Exposition, October 14–18, 2012; Chicago. Poster: M1150.Pasquali I. et al. Poster presentation at the 2012 AAPS Annual Meeting and Exposition, October 14–18, 2012; Chicago. Poster: M1150.Newman S.P. Principles of metered"dose inhaler design. Respir. Care. 2005; 50 (9): 1177–1790.Newman S.P. Principles of metered"dose inhaler design. Respir. Care. 2005; 50 (9): 1177–1790.Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC"free HFA"beclomethasone metereddose inhaler compared with CFC"beclomethasone. Eur. Respir. J. 1998; 12 (6): 1346–1353.Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC"free HFA"beclomethasone metereddose inhaler compared with CFC"beclomethasone. Eur. Respir. J. 1998; 12 (6): 1346–1353.Hochrainer D., Hölz H., Kreher C. et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J. Aerosol. Med. 2005; 18 (3): 273–282.Hochrainer D., Hölz H., Kreher C. et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J. Aerosol. Med. 2005; 18 (3): 273–282.Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2011; 105 (6): 930–938.Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2011; 105 (6): 930–938.Pitcairn G., Reader S., Pavia D., Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J. Aerosol. Med. 2005; 18 (3): 264–272.Pitcairn G., Reader S., Pavia D., Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J. Aerosol. Med. 2005; 18 (3): 264–272.Ciciliani A., Wachtel H., Langguth P. Comparing Respimat Soft Mist inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respir. Drug Delivery. 2014; 2: 453–456.Ciciliani A., Wachtel H., Langguth P. Comparing Respimat Soft Mist inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respir. Drug Delivery. 2014; 2: 453–456.Ciciliani A., Wachtel H., Heussel C., Langguth P. Evaluation of Respimat Soft Mist inhaler based on in vitro measurements and CFD simulations. Respir. Drug Delivery. 2015; 2: 357–362.Ciciliani A., Wachtel H., Heussel C., Langguth P. Evaluation of Respimat Soft Mist inhaler based on in vitro measurements and CFD simulations. Respir. Drug Delivery. 2015; 2: 357–362.van Noord J.A., Cornelissen P.J., Aumann J.L. et al. The efficacy of tiotropium administered via Respimat Soft Mist inhaler or HandiHaler in COPD patients. Respir. Med. 2009; 103 (1): 22–29.van Noord J.A., Cornelissen P.J., Aumann J.L. et al. The efficacy of tiotropium administered via Respimat Soft Mist inhaler or HandiHaler in COPD patients. Respir. Med. 2009; 103 (1): 22–29.

The authors declare that there are no conflicts of interest present.